Given a paragraph and a claim, classify it this way: If the claim contradicts the evidence present in the paragraph, classify the claim as '0'. If the claim has multiple supporting *AND* contradicting evidences, classify the claim as '1'. If the claim has supporting evidence and the paragraph is in overall favor of the claim, then classify the claim as '2'.

Input: Consider Input: Paragraph: The release does not include any cost information. The summary gives anabsolute risk reduction percentage of 0.27% for patients who received radiation compared to those who did not. It also includes the number needed to treat (370) to save one patient. This is good detail, but we would also have liked more context on the controversies of DCIS treatment. A HealthNewsReview.org podcast provides a deeper look here. The release briefly discusses harms. The release says patients who received radiation and lumpectomy had more "local" recurrences of the cancer, but their overall survival was modestly better than patients who did not have radiation (a 0.27% reduction over 15 years). The release should have given some mention to the harms of radiation treatment, particularly since the potential benefit of radiotherapy was very small. The release provides details on the association study, which reviewed records from thousands of patients. The release also includes limitations of the study. There is no disease mongering. The release provides context on the prevalence of DCIS in the U.S. The style of this news release was to punt the question of funders and "conflicts" into a web link where the reader has to chase it down. It would better serve readers to have funders and any conflicts of interest spelled out in the release. Here is what the release states: Editor's Note:The article contains conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc. The study notes that researchers received funding from Canadian government agencies. The release let readers down in providing the broader context about controversies over appropriate treatment if any for women diagnosed with DCIS. It's common knowledge that radiation and surgery are widely available treatments. There was no claim of novelty. The release stated that results are based on an association study of a national database containing more than 140,000 patient records. It's unclear if similar studies have been completed. We found no unjustifiable language. Claim: Association of radiation therapy plus lumpectomy in reduced risk of dying in women with DCIS

Output: 1

Input: Consider Input: Paragraph: P&G, with roughly $68 billion in annual revenue, said it has invested millions in creating and testing refills for detergents over the years and is now trying to push in to mainstream beauty and body care refills which are virtually unheard of. It recently began offering some Olay face-cream jars with refill pouches on Olay.com, telling Reuters it has plans to expand the sales of the pouches in Europe early next year. "We're learning on our legs so I don't know that we're in a position to say, 'Hey, here's the magic to selling refills,'" P&G spokesman Damon Jones said. Beauty products retailer The Body Shop, owned by Brazil's Natura Cosmeticos SA NATU3.SA, says it plans to roll out "refill stations" in its stores globally next year, allowing shoppers to buy reusable metal containers to fill with Body Shop shower gels or creams. The company had offered refills at its stores in the early 1990s, but discontinued them in 2003, citing a lack of consumer demand. Unilever, which has set targets for reducing and recycling plastic by 2025, in October announced the planned launch of "refill sticks" of deodorants under its Dove line of personal care products on Loopstore.com. The website, operated by recycling company TerraCycle, offers consumers the chance to buy some household products in ultra-durable packaging with refills delivered to their doors, milkman-style. Across the consumer goods industry, results for refillable products have been mixed so far as many shoppers are far too set in their ways to be easily weaned from living in a throwaway culture. While refills are less expensive to purchase - generally priced at 20% to 30% less per item than the containers they are aimed to replenish, according to Unilever - shoppers have so far, for the most part, failed to snap them up, the companies said. SC Johnson & Son Inc, marketer of Windex and Pledge, said refills and concentrates so far have not played well with either Americans or Europeans over the decade they have been offered, with unit sales of such products pretty much flat. It pulled concentrated refills for Shout stain remover off the shelves because they were not selling very well. In 2010, Unilever put 20-liter tanks to dispense detergents in Walmart Inc's (WMT.N) British supermarket chain Asda, and provided flexible pouches for customers to refill. But with leaky machines, safety and maintenance problems and the high costs of upkeep, Unilever said the tests fell short of expectations. Asda was also unhappy because the tanks occupied a lot of space. "None of them sell very well it is a convenience issue," SC Johnson CEO Fisk Johnson told Reuters. Johnson said some people find it painstaking to wash and refill bottles themselves while others worry that smaller bottles filled with concentrates are less "bang-for-your-buck" than the larger ones they have used for years. Still, the privately held company said it was expanding its refill offerings this year to address concerns surrounding plastic waste and is also testing refill stations for cleaning products with UK retailer Waitrose, owned by Britain's John Lewis [JLPLC.UL]. The Waitrose tests are showing the first signs of progress in refill sales, Johnson said, and the company is now thinking of expanding the project. Even if consumers are comfortable using refills for some household goods, it is more complicated to sell them for products like Pantene shampoo and Olay creams, P&G spokesman Jones said. For instance, with beauty products, the look and feel of packaging is a big factor in creating and maintaining customer loyalty, while delivering an environmental benefit, he said. Some shoppers say they want to buy refillable products, but that the offerings are not available at many stores. Earlier this year, dozens of consumers took to social media to urge The Body Shop to bring back its refill counters. "Refill, refill, refill!" Twitter user @JaiChipperfield said on July 22, joining a thread in which several other shoppers demanded the return of refills. "Seems to me that judging by these comments your customers want to see the return of refills," @JaiChipperfield added. "Me too, it would be brilliant to see that return." The Body Shop eventually responded to those pleas. "Now with the renewed focus on sustainability, we believe it is the right time to return with it," Body Shop spokeswoman Lucy Muircroft told Reuters this week. Claim: Procter & Gamble, rivals take refills into beauty aisle.

Output: 2

Input: Consider Input: Paragraph: About 1.3 million people worldwide died of TB in 2017. A further 300,000 people with both HIV and TB died in last year, according to World Health Organization figures released this month. Once referred to as 'consumption' because of the way sufferers appear to waste away, tuberculosis has been known for centuries. The bacterium responsible for TB was discovered 136 years ago and the development of an effective antibiotic helped rich countries to largely contain the disease after World War II. Still, the U.N. health agency estimates that about 10 million people worldwide become newly infected with TB each year, mostly in poor countries where access to health care is limited. "It really is a global epidemic," said Dr. Tereza Kasaeva, who heads WHO's program to combat TB. Speaking ahead of a high-level meeting on the sidelines of the U.N. General Assembly, Kasaeva said the U.N.'s target of eradicating tuberculosis worldwide by 2030 "is very ambitious given that for now progress is too slow." Like HIV, tuberculosis remains a highly stigmatized illness, preventing some sufferers from seeking treatment. Experts are particularly concerned about the rising number of people contracting drug-resistant variants of TB, many of which aren't diagnosed properly. Treating them can be costly and arduous, requiring years of medication with strong side effects. Dr. Ralf Otto-Knapp of the German Central Committee to Combat Tuberculosis, a group established in the late 19th century when the disease was still widespread in much of Europe, warned against complacency about the disease in an age of global travel. "Because of the increasing mobility in society it also affects economically more powerful countries," he said. "We need a joint political will and the necessary resources to fight tuberculosis effectively." Kasaeva said she hoped leaders attending the New York meeting Wednesday will commit to closing the growing gap between the amount of money available and the billions more required to tackle the disease. Campaigners applauded a recent decision by the World Health Organization to recommend a change in the way drug-resistant tuberculosis is treated, prioritizing oral drugs over injectable medication. The group Doctors Without Borders said such treatment can reduce debilitating side effects, help improve cure rates and cut the number of deaths, but noted that it requires U.S. pharmaceutical giant Johnson & Johnson, which makes the key drug bedaquiline, to reduce its price in low- and middle-income countries with high rates of drug-resistant TB. The company has already sharply reduced costs for the drug in some countries, but in others a six-month course of treatment can cost several thousand dollars far more than most people can afford. Companies have been reluctant to invest in developing TB medication with only two new drugs coming onto the market in the past 50 years. Claim: Governments to discuss tackling tuberculosis at UN summit.
Output: 2